Vera: Long-term disease modificatinton supports atacicept’s potential to prevent kidney failure

 

• Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;
  
• Long-term results from the ORIGIN Phase 2b study were simultaneously published in the Journal of the American Society of Nephrology;
  
• Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET

The Company will host an investor call and webcast to discuss the data update on Monday, October 28, at 8:00 AM ET. The live webcast will be available on the Company’s Investor Calendar at https://ir.veratx.com/news-events/investor-calendar, with the recording and presentation available immediately following the event.

The Kidney Week 2024 presentation and posters are available on the Company’s website at https://ir.veratx.com/news-events/presentations.

https://www.globenewswire.com/news-release/2024/10/26/2969705/0/en/Vera-Therapeutics-Announces-96-week-eGFR-Stabilization-in-ORIGIN-Phase-2b-Study-of-Atacicept-in-IgAN-in-a-Late-Breaking-Oral-Presentation-at-the-American-Society-of-Nephrology-Kidn.html